Allena Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Allena Pharmaceuticals Inc.
Alnylam Shows Efficacy, Safety With Lumasiran In Vulnerable Pediatric Patients
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.
Allena Bets On Its Kidney Stone Treatment Despite Placebo Concerns
Execs are hoping having positive results in two studies will help raise funds for continued development. But high placebo results have caused concern for investors.
Keeping Track: A Burst Of Breakthroughs, A Priority Review For Keytruda, And Some Supplemental Submissions
The latest drug development news and highlights from our US FDA Performance Tracker.
Alnylam Plans Lumasiran Phase III As Market Landscape Gets Competitive
Alnylam will take on the global development and commercialization of investigational rare disease therapy lumasiran as Sanofi declines to opt-in to its development, and the US biotech prepares to commercialize its first RNAi therapeutic, pencilled in for later this year.
- Drug Delivery
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.